

Applicant : Yousef Al-Abed
Appl. No. : 10/594,641
Filed : March 28, 2008

Claim Amendments

A listing of the claims, including Claims 1 and 3 as currently amended, Claims 2, 4-8, 14-20 as currently canceled, and new Claims 26-28 as added, is set forth below.

1. (Currently Amended) A method of treating a mammal having type 1 diabetes or at risk for type 1 diabetes, the method comprising administering to the mammal a pharmaceutical composition comprising an agent that inhibits a macrophage migration inhibitory factor (MIF) in the mammal, wherein the agent comprises a binding site of an antibody that binds specifically to the MIF ~~is a polypeptide or a polynucleotide~~.

2. (Canceled).

3. (Currently Amended) The method of claim 1 ~~2~~, wherein the agent is an antibody.

4-8. (Canceled).

9. (Original) The method of claim 1, wherein the mammal has or is at risk for having diabetes, impaired glucose intolerance, stress hyperglycemia, metabolic syndrome, and/or insulin resistance.

10. (Original) The method of claim 1, wherein the mammal is a rodent.

11. (Original) The method of claim 1, wherein the mammal is a human.

12-25. (Canceled).

Applicant : Yousef Al-Abed
Appl. No. : 10/594,641
Filed : March 28, 2008

26. (New) The method of claim 1, wherein the agent is an Fab fragment or an F(ab)₂ fragment.

27. (New) The method of claim 3, wherein the antibody is a monoclonal antibody.

28. (New) The method of claim 3, wherein the antibody is a humanized antibody.